Site maintenance Wednesday, November 13th, 2024. Please note that access to some content and account information will be unavailable on this date.
Skip to main content
Full access
Editorials
Published Online: 2 February 2022

Accelerated Intermittent Theta Burst Stimulation: Expediting and Enhancing Treatment Outcomes in Treatment-Resistant Depression

Major depressive disorder is a highly prevalent condition (1), estimated to affect approximately 280 million people worldwide (2). It is well established that a significant proportion—approximately one-third—of individuals with major depression develop treatment-resistant depression after failing to respond to first-line therapies (3). In fact, the 12-month prevalence of treatment-resistant depression is 2.76 million in the United States alone (4). There remains a strong need for effective treatments in this population. In this issue, Cole et al. (5) report findings on a new treatment protocol developed to rapidly and effectively treat individuals with treatment-resistant depression.
The Cole et al. study demonstrates safety and significant efficacy of Stanford neuromodulation therapy (SNT) in a placebo-controlled design with 29 participants. In this protocol, patients are treated with repetitive transcranial magnetic stimulation (rTMS) 10 times per day over the course of a week, with 50 minutes between each brief treatment. Each treatment consists of a total of 1,800 pulses of intermittent theta burst stimulation (iTBS) rTMS over the left dorsolateral prefrontal cortex (DLPFC), localized by MRI. Stimulation is at 90% of resting motor threshold. The authors of the SNT protocol previously published findings on their accelerated rTMS treatment, identical to the treatment of focus in this article, in uncontrolled trials. They showed the potential of this rapid treatment protocol in a sample of six patients with highly treatment-resistant depression, among whom five met criteria for response and four for remission at end of treatment (6). In a follow-up study, with a sample of 21 patients, they found response and remission rates of 90% at treatment end (7). Their use of a placebo control in this latest study is important given the relatively high likelihood of a placebo response in treatment-resistant depression (8) and in accelerated rTMS protocols (9), since the treatment involves intensive patient involvement over a 5-day treatment program. The authors successfully maintained the blind throughout the study, and there were limited differences in side effects between groups, with headache in the active treatment group being the only one that was significantly greater. In terms of the primary outcomes, the authors reported an impressive 69.2% response rate and a 46.2% remission rate 4 weeks after treatment, with a very large effect size (Cohen’s d) of 1.4. They justifiably compare their outcomes to ECT, the gold-standard treatment in this patient group.
Other research groups have previously demonstrated the feasibility, safety, and efficacy of accelerated TBS. Compared with the SNT protocol, however, these studies included far fewer sessions per day and alternative treatment parameters with regard to percent resting motor threshold of treatment, time period between treatments, and laterality of treatment target (1013). None of these previous studies have delivered the large remission rates demonstrated in the SNT protocol.
The Cole et al. study represents a significant therapeutic innovation for the use of rTMS as a treatment for major depressive disorder. There has long been a general understanding in the field of noninvasive brain stimulation that given the wide range of available treatment parameters that rTMS affords, there would be significant room for improvements in treatment design for major depression. The first rTMS treatment approved by the U.S. Food and Drug Administration for major depression was a 10-Hz protocol taking up to 37.5 minutes and given once a day for 4–6 weeks, which was effective but grossly inefficient as an interventional treatment. The next significant advance was approval of a condensed variant of rTMS, theta burst stimulation (TBS). The impetus for the development of TBS came from preclinical studies exploring neuroplastic effects of a form of brain stimulation that mimics the endogenous burst discharges in the theta range on EEG (14). The 10-Hz and the iTBS protocols were found to be equally efficacious (15), and similar to the 10-Hz protocol, iTBS was initially approved to be delivered once a day, but over a short 3-minute period, which was a significant reduction in treatment time. Ultimately, this considerable reduction in protocol time subsequently freed up researchers to experiment with accelerated treatment schedules, leading to major opportunities for pragmatic improvements in the growing field of rTMS, and leading to our discussion here.
While the SNT protocol demonstrates strong treatment effects in this study, there are some questions with regard to study design and patient inclusion, which may limit the generalizability and full adoption of this treatment innovation in the treatment-resistant depression population. First, the severity of treatment-resistant depression and level of treatment resistance in the study sample appears to be moderate, not severe, owing partially to the relatively few failed medication trials during the current episode (the mean number of adequate antidepressant trials in the current episode was two for the active treatment group and one for the sham treatment group). It remains to be seen how effective this treatment will be in patients with more severe illness in whom ECT is commonly used (e.g., inpatients or those with emergent suicidality [16]). Nevertheless, the logistics of delivering SNT may actually be more practical for a patient who is already stationed in a hospital setting all day. It may be difficult for patients employed full-time to lose an entire work week, especially given the limited evidence on the long-term durability of response with SNT (the response and remission rates declined by week 4 in this study). It is therefore not yet clear who the optimal target population is for this treatment. The other issue with generalizability here is that the authors use an MRI-guided technique to localize treatment to the left DLPFC. Recent advances in these methods have improved the ability to optimally target specific locations within the DLPFC. What has yet to be determined is whether these methods lead to improved remission rates above standard targeting techniques (17). Moreover, MRI-guided targeting of the DLPFC could be prohibitive for clinics running small margins, or for patients who are partially insured. Lastly, only 16% of individuals screened online were included in this study, which implies that patients were carefully selected. Even so, the overall results are both exciting and compelling, and follow-up studies with the SNT approach are currently under way.
There is a growing body of evidence to support the notion that targeting the left DLPFC with rTMS dynamically changes the connection of this brain region with the subgenual cingulate cortex, an area strongly implicated in the pathophysiology of major depression (18, 19). This theory suggests that rTMS activates the underactive left DLPFC in depressed individuals, which in turn reduces overactive subgenual cingulate cortex activity in major depression, possibly through a long-term potentiation method at the neuronal level. In fact, there is some preclinical evidence to support the specific 50–60 minute intertreatment window in the SNT protocol as a component of the treatment that enhances clinical improvement through the process of additive metaplasticity on the cell and circuit level (20). Metaplasticity refers to the process of change in magnitude or direction of plasticity; put more simply, it is plasticity of neuroplasticity. Thus, treatment with the SNT protocol may, in theory, accelerate neuroplasticity through metaplastic effects on the magnitude and intensity of TBS-induced neuroplasticity. This could be one reason why the SNT protocol yields such strong effects while earlier accelerated protocols with shorter intertreatment windows far shorter than 50 minutes did not. A large open-label accelerated trial currently under way has also found robust responses with this same intertreatment window, albeit with only 600 pulses per treatment (D. Blumberger et al., personal communication). It still remains to be determined whether the intertreatment interval (50 minutes) is necessary to produce the robust treatment response or whether this is simply a reflection of the uniquely very high number of stimuli delivered daily in SNT (18,000). While it has been suggested that repeated sessions of iTBS produce neuroplasticity to achieve the beneficial effects of accelerated iTBS in depression (20), this has recently been called into question (21). Hence, the high number of pulses delivered in an even shorter time window (i.e., between 1 and 2 hours) may potentially achieve comparable results, and such trials should be considered.
With the growing acceptance of accelerated TBS treatments by physicians, researchers, and patients, a new avenue of rTMS research is now open. Future studies in this area should further refine treatment parameters and investigate the role for accelerated protocols in other psychiatric diseases, such as bipolar depression and severe treatment-resistant depression in the inpatient setting. Further study of these treatment approaches may lead to improved outcomes in a substantial proportion of patients, offering tremendous hope for those who suffer with disabling conditions.

REFERENCES

1.
Kessler RC, Berglund P, Demler O, et al: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095–3105
2.
Global Health Data Exchange, Institute of Health Metrics and Evaluation, 2019
3.
Rush AJ, Trivedi MH, Wisniewski SR, et al: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905–1917
4.
Zhdanava M, Pilon D, Ghelerter I, et al: The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry 2021; 82:20m13699
5.
Cole EJ, Phillips AL, Bentzley BS, et al: Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry 2022; 179:132–141
6.
Williams NR, Sudheimer KD, Bentzley BS, et al: High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain 2018; 141:e18
7.
Cole EJ, Stimpson KH, Bentzley BS, et al: Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression. Am J Psychiatry 2020; 177:716–726
8.
Jones BDM, Razza LB, Weissman CR, et al: Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Netw Open 2021; 4:e2125531
9.
Baeken C, Wu GR, van Heeringen K: Placebo aiTBS attenuates suicidal ideation and frontopolar cortical perfusion in major depression. Transl Psychiatry 2019; 9:38
10.
Bröcker E, van den Heuvel L, Seedat S: Accelerated theta-burst repetitive transcranial magnetic stimulation for depression in South Africa. S Afr J Psychiatr 2019; 25:1346
11.
Duprat R, Desmyter S, Rudi R, et al: Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: a fast road to remission? J Affect Disord 2016; 200:6–14
12.
Chen L, Thomas EHX, Kaewpijit P, et al: Accelerated theta burst stimulation for the treatment of depression: a randomised controlled trial. Brain Stimul 2021; 14:1095–1105
13.
Fitzgerald PB, Chen L, Richardson K, et al: A pilot investigation of an intensive theta burst stimulation protocol for patients with treatment resistant depression. Brain Stimul 2020; 13:137–144
14.
Suppa A, Huang YZ, Funke K, et al: Ten years of theta burst stimulation in humans: established knowledge, unknowns, and prospects. Brain Stimul 2016; 9:323–335
15.
Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al: Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet 2018; 391:1683–1692
16.
Weissman CR, Hadas I, Yu D, et al: Predictors of change in suicidal ideation across treatment phases of major depressive disorder: analysis of the STAR*D data. Neuropsychopharmacology 2021; 46:1293–1299
17.
Fitzgerald PB: Targeting repetitive transcranial magnetic stimulation in depression: do we really know what we are stimulating and how best to do it? Brain Stimul 2021; 14:730–736
18.
Hadas I, Zomorrodi R, Hill AT, et al: Subgenual cingulate connectivity and hippocampal activation are related to MST therapeutic and adverse effects. Transl Psychiatry 2020; 10:392
19.
Cash RFH, Cocchi L, Lv J, et al: Functional magnetic resonance imaging-guided personalization of transcranial magnetic stimulation treatment for depression. JAMA Psychiatry 2021; 78:337–339
20.
Thomson AC, Sack AT: How to design optimal accelerated rTMS protocols capable of promoting therapeutically beneficial metaplasticity. Front Neurol 2020; 11:599918
21.
Boucher PO, Ozdemir RA, Momi D, et al: Sham-derived effects and the minimal reliability of theta burst stimulation. Sci Rep 2021; 11:21170

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 85 - 87
PubMed: 35105163

History

Accepted: 14 December 2021
Published in print: February 2022
Published online: 2 February 2022

Keywords

  1. Neurostimulation
  2. Depressive Disorders
  3. Major Depressive Disorder

Authors

Details

Department of Psychiatry, University of California San Diego, La Jolla.
Zafiris J. Daskalakis, M.D., Ph.D. [email protected]
Department of Psychiatry, University of California San Diego, La Jolla.

Notes

Send correspondence to Dr. Daskalakis ([email protected]).

Funding Information

Dr. Weissman receives funding from the Brain and Behavior Research Foundation. Dr. Daskalakis has received research and equipment in-kind support for an investigator-initiated study through BrainsWay and MagVenture; he serves on the scientific advisory board of BrainsWay; and his work has been supported by NIMH, the Canadian Institutes of Health Research, Brain Canada, and the Temerty Family and Grant Family Foundations.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share